[{"command":"openDialog","selector":"#drupal-modal","settings":null,"data":"\u003Cdiv id=\u0022republish_modal_form\u0022\u003E\u003Cform class=\u0022modal-form-example-modal-form ecl-form\u0022 data-drupal-selector=\u0022modal-form-example-modal-form\u0022 action=\u0022\/en\/article\/modal\/6855\u0022 method=\u0022post\u0022 id=\u0022modal-form-example-modal-form\u0022 accept-charset=\u0022UTF-8\u0022\u003E\u003Cp\u003EHorizon articles can be republished for free under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence.\u003C\/p\u003E\n \u003Cp\u003EYou must give appropriate credit. We ask you to do this by:\u003Cbr \/\u003E\n 1) Using the original journalist\u0027s byline\u003Cbr \/\u003E\n 2) Linking back to our original story\u003Cbr \/\u003E\n 3) Using the following text in the footer: This article was originally published in \u003Ca href=\u0027#\u0027\u003EHorizon, the EU Research and Innovation magazine\u003C\/a\u003E\u003C\/p\u003E\n \u003Cp\u003ESee our full republication guidelines \u003Ca href=\u0027\/horizon-magazine\/republish-our-stories\u0027\u003Ehere\u003C\/a\u003E\u003C\/p\u003E\n \u003Cp\u003EHTML for this article, including the attribution and page view counter, is below:\u003C\/p\u003E\u003Cdiv class=\u0022js-form-item form-item js-form-type-textarea form-item-body-content js-form-item-body-content ecl-form-group ecl-form-group--text-area form-no-label ecl-u-mv-m\u0022\u003E\n \n\u003Cdiv\u003E\n \u003Ctextarea data-drupal-selector=\u0022edit-body-content\u0022 aria-describedby=\u0022edit-body-content--description\u0022 id=\u0022edit-body-content\u0022 name=\u0022body_content\u0022 rows=\u00225\u0022 cols=\u002260\u0022 class=\u0022form-textarea ecl-text-area\u0022\u003E\u003Ch2\u003EWant to cure disease? Repurpose the body\u2019s cells\u003C\/h2\u003E\u003Cp\u003EMillions of Europeans are affected by stress urinary incontinence (SUI) which can have a devastating effect on quality of life. Between 20% and 50% of women are affected by the condition, which can result from damage to bladder-closing muscles during childbirth, affecting their work, social and family lives. Men too can suffer from SUI, particularly those who have undergone surgery for prostate cancer.\u003C\/p\u003E\u003Cp\u003EOnce muscle fibres in the bladder\u2019s sphincter have been damaged, the muscle may not recover the strength and flexibility needed to close the bladder. Current treatments offer some short-term relief to the symptoms of SUI but there is no effective cure.\u003C\/p\u003E\u003Cp\u003ENow, researchers are trying a new kind of therapy that aims to fix the sphincter by implanting stem cells taken from the patients\u2019 own leg muscles. Before injecting them into the sphincter, millions of these cells must be produced in the lab.\u003C\/p\u003E\u003Cp\u003E\u2018We take a biopsy from a leg muscle that is not used very often,\u2019 explains Dr Deana Mohr, University Hospital Zurich and University of Zurich, Switzerland. \u2018Stem cells are then isolated and expanded before being injected into the patient\u2019s bladder sphincter.\u2019\u003C\/p\u003E\u003Cp\u003E\u003Cblockquote class=\u0022tw-text-center tw-text-blue tw-font-bold tw-text-2xl lg:tw-w-1\/2 tw-border-2 tw-border-blue tw-p-12 tw-my-8 lg:tw-m-12 lg:tw--ml-16 tw-float-left\u0022\u003E\n \u003Cspan class=\u0022tw-text-5xl tw-rotate-180\u0022\u003E\u201c\u003C\/span\u003E\n \u003Cp class=\u0022tw-font-serif tw-italic\u0022\u003E\u0026#039;The stem cells are stimulated by electro-magnetic pulses and start rebuilding the sphincter muscle.\u0026#039;\u003C\/p\u003E\n \u003Cfooter\u003E\n \u003Ccite class=\u0022tw-not-italic tw-font-normal tw-text-sm tw-text-black\u0022\u003EDr Deana Mohr, University Hospital Zurich and University of Zurich, Switzerland\u003C\/cite\u003E\n \u003C\/footer\u003E\n\u003C\/blockquote\u003E\n\u003C\/p\u003E\u003Cp\u003EDr Mohr coordinates of a project called MUSIC, which is applying years of research on stem cells and regenerative medicine in a study of 40 women with SUI. It is the first trial of its kind in human volunteers and will conclude within five years.\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003ESevere\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003EThe study initially focuses on patients with mild SUI but could eventually be used in people with severe forms of the condition. \u2018Patients with more severe diseases or who have undergone surgery may have suffered serious damage to their muscle,\u2019 said Dr Mohr. \u2018They would need a larger volume of new tissue so we want to show the effectiveness of treating milder cases first before moving to patients with severe SUI.\u2019\u003C\/p\u003E\u003Cp\u003EAfter the new cells are implanted, the researchers use neuromuscular electro-magnetic stimulation to train pelvic floor muscles. Patients sit on a specially designed chair for 20 minutes while it emits electro-magnetic pulses. Like a major physical workout at the gym, patients can feel a little sore after the training session, but the repeated muscle contractions help switch the new cells on.\u003C\/p\u003E\u003Cp\u003E\u2018The stem cells are stimulated by electro-magnetic pulses and start rebuilding the sphincter muscle,\u2019 said Dr Mohr. \u2018They identify areas where muscle fibres are missing or damaged and begin to fuse into muscle fibres where they are needed.\u2019\u003C\/p\u003E\u003Cp\u003EEach patient is treated with their own cells, making the process quite time-consuming. The cells are developed in a special laboratory that meets strict standards and can take three to four weeks for each patient.\u003C\/p\u003E\u003Cp\u003EDr Jenny Prange at the tissue engineering lab in the University of Zurich and University Hospital Zurich said: \u2018We can work on several patients\u2019 cells in parallel, provided they are each grown spatially separated in incubators to reduce any risk of contamination. It\u2019s quite labour intensive but the goal for the future is to reduce the timescale by including a bioreactor for the cell production, so that it could eventually become a more routine procedure.\u2019\u003C\/p\u003E\u003Cp\u003EThe cost of treating each patient is currently high but if the process can be scaled up and made more efficient, this kind of stem cell treatment could be accessible to many more patients who need it. This approach potentially may also benefit people suffering faecal incontinence or other conditions caused by the loss of functional muscle tissue.\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003EPace\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003EUsing a patient\u2019s own cells as a therapy reduces the risk that implanted tissue would be rejected. However, the slow pace of producing these personalised therapies is currently a major technical challenge.\u003C\/p\u003E\u003Cp\u003EOne way to overcome this is to use stem cells donated by healthy donors. These cells can be expanded and stored in vials in nitrogen tanks ready to be used as an off-the-shelf product. One of the first disease areas to benefit from advances in this field may be ischaemic heart disease \u2013 a common cause of death and hospitalisation in developed countries. Over 4 million deaths in Europe are caused by heart disease every year.\u003C\/p\u003E\u003Cp\u003EResearchers on a project called SCIENCE are testing whether donated stem cells from adipose tissue in the abdomen could be used to reverse heart disease. These cells\u0026nbsp;have the potential\u0026nbsp;to form new blood vessels and heart muscle. While it takes several weeks to grow enough cells to implant in each patient, these donor stem cell lines are a promising new source of replacement heart tissue.\u003C\/p\u003E\u003Cp\u003EProfessor Jens Kastrup, director of the cardiac stem cell centre at Rigshospitalet University of Copenhagen, Denmark, leads the consortium which is running human trials in 220 patients with heart failure. All are being given standard treatment while some are also offered the new therapy. This will show whether the stem cell treatment offers additional benefits compared to normal medication alone.\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003EInitial\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003EAn initial study of 60 patients with coronary artery disease and heart failure has shown improved cardiac pump function and improved quality of life after stem cell therapy. These patients\u2019 hearts are now pumping more efficiently, resulting in fewer hospitalisations.\u003C\/p\u003E\u003Cp\u003EWhile the current larger trial is still ongoing, the team hopes to apply to the European Medicines Agency for a licence to market the therapy through a spin-off company - Cell2Cure ApS. The consortium already has a patent on their technology but will need data on successfully treated patients if they are to convince regulators to approve it.\u003C\/p\u003E\u003Cp\u003E\u2018If the trial goes well, a therapy could be approved in five years \u2013 but there is much work to do before we reach that point,\u2019 said Prof. Kastrup.\u003C\/p\u003E\u003Cp\u003EThe demand for effective stem cell therapies of this kind could be high, given the burden of disease. The researchers would need to scale up production of the treatment if it secures approval \u2013 potentially building a new cell production facility or working with an established biopharma company to bring the therapy to patients.\u003C\/p\u003E\u003Cp\u003EIf the heart failure therapy proves successful, it could be adapted for patients with other serious conditions. \u2018Potentially, the same stem cell lines that we have produced could be tested in arthritis, disc regeneration in the back, Crohn\u2019s disease and multiple sclerosis,\u2019 said Prof. Kastrup. \u2018It may also help reduce the rejection of organ transplantation.\u2019\u003C\/p\u003E\u003Cp\u003E\u003Cem\u003EThe research in this article was funded by the EU. If you liked this article, please consider sharing it on social media.\u003C\/em\u003E\u003C\/p\u003E\u003Cp\u003E\u003Ca href=\u0022http:\/\/bit.ly\/newsalertsignup\u0022 target=\u0022_blank\u0022 rel=\u0022noopener noreferrer\u0022\u003E\u003Cimg src=\u0022https:\/\/horizon-magazine.eu\/research-and-innovation\/sites\/default\/files\/hm\/news-alert-final.jpg\u0022 alt width=\u0022983\u0022 height=\u0022222\u0022\u003E\u003C\/a\u003E\u003C\/p\u003E\u003C\/textarea\u003E\n\u003C\/div\u003E\n\n \u003Cdiv id=\u0022edit-body-content--description\u0022 class=\u0022ecl-help-block description\u0022\u003E\n Please copy the above code and embed it onto your website to republish.\n \u003C\/div\u003E\n \u003C\/div\u003E\n\u003Cinput autocomplete=\u0022off\u0022 data-drupal-selector=\u0022form-y6jk51vbzs6ye5ddrxodumfiwimc6hewu5l0qqhxcji\u0022 type=\u0022hidden\u0022 name=\u0022form_build_id\u0022 value=\u0022form-y6JK51vbzS6Ye5ddRXODUMFiwIMC6hEWU5L0qqhXCjI\u0022 \/\u003E\n\u003Cinput data-drupal-selector=\u0022edit-modal-form-example-modal-form\u0022 type=\u0022hidden\u0022 name=\u0022form_id\u0022 value=\u0022modal_form_example_modal_form\u0022 \/\u003E\n\u003C\/form\u003E\n\u003C\/div\u003E","dialogOptions":{"width":"800","modal":true,"title":"Republish this content"}}]